Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems that not even bad news lasts forever.
Jon C. Ogg Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan, T-Mobile, Verizon Communications and Wells Fargo.
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.
Chris Lange Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday, and analysts' expectations are mild overall.
Chris Lange Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto, Roku, Square, Tilray and Twilio.
Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to a man accusing the drugmaker of failing to warn about the side…
Chris Lange One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.
Chris Lange Five drugmakers are considering a proposal that would have them contribute to a trust established as part of the bankruptcy settlement by Purdue Pharmaceuticals and be released from liability in the hundreds…
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
As, when and if ESG themes continue to gain in popularity, imagine what could happen to some of the top-ranked ESG companies. Imagine also what could happen to some of the companies…
Johnson & Johnson is trading higher on the news, but some smaller public companies tied into the opioid crisis are taking it on the chin.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Johnson & Johnson shares took a hit after earnings, but it was more than just the earnings and guidance to blame. Some rivals may have been winning at the company's expense.
